Sharon Cresci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4989228/publications.pdf

Version: 2024-02-01

35 papers	1,565 citations	471509 17 h-index	395702 33 g-index
35 all docs	35 docs citations	35 times ranked	3716 citing authors

#	Article	IF	Citations
1	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518, 102-106.	27.8	581
2	Î²₂-Adrenergic Receptor Genotype and Survival Among Patients Receiving Î²-Blocker Therapy After an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2005, 294, 1526.	7.4	177
3	Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure. Journal of the American College of Cardiology, 2009, 54, 432-444.	2.8	105
4	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	11.4	84
5	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
6	COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. Mayo Clinic Proceedings, 2021, 96, 446-463.	3.0	62
7	A novel genetic marker of decreased inflammation and improved survival after acute myocardial infarction. Basic Research in Cardiology, 2018, 113, 38.	5.9	58
8	Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel-Treated Patients After Acute Myocardial Infarction. Circulation: Cardiovascular Genetics, 2014, 7, 277-286.	5.1	50
9	Adrenergic-Pathway Gene Variants Influence Beta-Blockerâ€“Related Outcomes After Acute Coronary Syndrome in a Race-Specific Manner. Journal of the American College of Cardiology, 2012, 60, 898-907.	2.8	35
10	Epithelial Neutrophil-Activating Peptide (ENA-78), Acute Coronary Syndrome Prognosis, and Modulatory Effect of Statins. PLoS ONE, 2008, 3, e3117.	2.5	32
11	Peroxisome Proliferator-Activated Receptor Pathway Gene Polymorphism Associated With Extent of Coronary Artery Disease in Patients With Type 2 Diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Circulation, 2011, 124, 1426-1434.	1.6	28
12	PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes, 2020, 69, 771-783.	0.6	28
13	CHRNA5 Variant Predicts Smoking Cessation in Patients With Acute Myocardial Infarction. Nicotine and Tobacco Research, 2014, 16, 1224-1231.	2.6	25
14	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. Diabetes, 2019, 68, 1649-1662.	0.6	22
15	Factors influencing patient willingness to participate in genetic research after a myocardial infarction. Genome Medicine, 2011, 3, 39.	8.2	21
16	Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohorts. Atherosclerosis, 2015, 242, 261-267.	0.8	21
17	A PPARÎ± Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes. PLoS ONE, 2010, 5, e12584.	2.5	18
18	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17

#	Article	IF	Citations
19	Interaction between PPARA genotype and Î²-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics, 2008, 9, 1403-1417.	1.3	16
20	Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. European Journal of Preventive Cardiology, 2015, 22, 779-787.	1.8	15
21	Investigation of 95 variants identified in a genome-wide study for association with mortality after acute coronary syndrome. BMC Medical Genetics, 2011, 12, 127.	2.1	14
22	The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Expert Opinion on Pharmacotherapy, 2005, 6, 2577-2591.	1.8	12
23	PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease. PPAR Research, 2008, 2008, 1-11.	2.4	11
24	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
25	Genetic Architecture of Circulating Very-Long-Chain (C24:0 and C22:0) Ceramide Concentrations. Journal of Lipid and Atherosclerosis, 2020, 9, 172.	3.5	10
26	Change in Angina Symptom Status After Acute Myocardial Infarction and Its Association With Readmission Risk: An Analysis of the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) Registry. Journal of the American Heart Association, 2016, 5, .	3.7	9
27	Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins and Other Lipid Mediators, 2018, 138, 15-22.	1.9	9
28	Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e021141.	3.7	9
29	Pharmacogenetics of thePPARgenes and cardiovascular disease. Pharmacogenomics, 2007, 8, 1581-1595.	1.3	7
30	Pulsus Alternans in Cardiogenic Shock Recapitulated in Single Cell Fluorescence Imaging of a Patientâ€™s Cardiomyocyte. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008855.	3.9	5
31	Recurrent Takotsubo Cardiomyopathy inÂa Patient With Hypertrophic Cardiomyopathy Leading to Cardiogenic Shock Requiring VA-ECMO. JACC: Case Reports, 2020, 2, 1014-1018.	0.6	4
32	From SNPs to Functional Studies in Cardiovascular Pharmacogenomics. Methods in Molecular Biology, 2008, 448, 379-393.	0.9	3
33	Exploring experiences of hypertrophic cardiomyopathy diagnosis, treatment, and impacts on quality of life among middle-aged and older adults: An interview study. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 788-793.	1.6	2
34	Phenylephrine Provocation to Evaluate the Cause of Mitral Regurgitation in Patients With Obstructive Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2021, 14, e012656.	2.6	1
35	CYP450 pharmacogenomics: a cardiology perspective. Personalized Medicine, 2015, 12, 59-62.	1.5	0